Neonatal Extubation Failure Prevention Trial Using Nebulised Epinephrine (NEPTUNE): A Randomized Controlled Trial.

Area of Science:

• Neonatal Intensive Care
• Pediatric Respiratory Medicine
• Clinical Trials

Background:

• Extubation failure (EF) is a significant concern in ventilated neonates, leading to increased morbidity and healthcare costs.
• Standard care protocols aim to minimize EF, but novel interventions are continually explored.
• Epinephrine nebulization is a potential treatment to reduce upper airway swelling and improve post-extubation outcomes.

Purpose of the Study:

• To determine if nebulized epinephrine, as an adjunct to standard care, can decrease extubation failure in neonates.
• To assess the impact of epinephrine nebulization on secondary outcomes, including respiratory distress and adverse events.

Main Methods:

• A randomized controlled superiority trial was conducted with 158 ventilated neonates.
• Participants were randomized to receive either standard care or standard care plus nebulized epinephrine post-extubation.
• The primary outcome was extubation failure, defined as reintubation within 48 hours.

Main Results:

• Intention-to-treat analysis showed no significant difference in EF rates between the epinephrine nebulization group and the standard care group (14.8% vs. 24.7%).
• Per-protocol analysis indicated a significant reduction in EF in the epinephrine group (9.2% vs. 24.7%).
• The epinephrine group showed significantly lower respiratory distress scores at 24 hours post-extubation, with no significant differences in adverse events.

Conclusions:

• Epinephrine nebulization administered after extubation did not significantly reduce the overall incidence of extubation failure in ventilated neonates.
• Despite not meeting the primary endpoint, the intervention showed a trend towards reduced respiratory distress.
• Further research may be warranted to explore specific subpopulations or optimized protocols for epinephrine nebulization in neonates.